The U.S. Food and Drug Administration has approved oxymetazoline hydrochloride ophthalmic solution 0.1% (Upneeq; Osmotica Pharmaceuticals) for the treatment of acquired blepharoptosis, according to a press release.
This if the first FDA-approved medical treatment for ptosis.
“Upneeq’s safety and efficacy profile and its once-a-day dosing provides a significant ophthalmic therapeutic innovation. Given the previous absence of any approved medical treatment options, ptosis has been often under-diagnosed or overlooked. Upneeq has the potential to address a significant unmet need in ptosis therapy,” stated Tina deVries, PhD, Executive Vice President, Research and Development, in a press release.
Read the full press release here.